Audentes’ gene therapy AT132 shows positive effect in XLMTM study; shares ahead 13% premarket – Seeking Alpha
|
Audentes' gene therapy AT132 shows positive effect in XLMTM study; shares ahead 13% premarket
Seeking Alpha Thinly traded Audentes Therapeutics (NASDAQ:BOLD) is up 13% premarket on light volume in response to its announcement of positive preliminary results from a Phase 1/2 clinical trial, ASPIRO, assessing gene therapy candidate AT132 in patients with X … |
